hemaCORE MDS (Myelodysplastic Syndrome) panel by FISH (Fluorescence In Situ Hybridization) detects specific chromosomal abnormalities associated with MDS. The panel includes analysis of Monosomy 5/Del(5q), Monosomy 7/Del(7q), Trisomy 8, and Del(20q), These tes...
DiagnosticsHealth package
For men & women168 hours4 testsHome collection
Know more about this package
hemaCORE MDS (Myelodysplastic Syndrome) panel by FISH (Fluorescence In Situ Hybridization) detects specific chromosomal abnormalities associated with MDS. The panel includes analysis of Monosomy 5/Del(5q), Monosomy 7/Del(7q), Trisomy 8, and Del(20q),...
hemaCORE MDS (Myelodysplastic Syndrome) panel by FISH (Fluorescence In Situ Hybridization) detects specific chromosomal abnormalities associated with MDS. The panel includes analysis of Monosomy 5/Del(5q), Monosomy 7/Del(7q), Trisomy 8, and Del(20q), These tests aid in the diagnosis, risk stratification, and prognostication of MDS patients. Detecting these chromosomal abnormalities provides valuable information for treatment decisions, including the use of targeted therapies, risk-adapted strategies, and determinin...
What does Myelodysplastic Syndrome (MDS) Panel measure?
Contains 4 tests
Myelodysplastic Syndrome (MDS) Panel includes Trisomy 8, Del20q, Del 5q, Del 7q.
Package contains 4 tests
Showing 4 of 4 tests
Trisomy 8 is relatively specific for myeloid disorders and is rarely observed in lymphoid disease. It is found in 10-15% of patients with acute myeloid leukemia (AML), 15-20% of patients with myelodysplastic syndromes (MDS), as a secondary abnormality in Philadelphia chromosome-positive CML, and another myeloproliferative disorder. Trisomy 8 occurs as the sole chromosome abnormality in about 40% of AML cases, occurs in combination with simple chromosome changes in 35% of cases, and as part of a complex karyotype in 25% of AML patients. This test uses the FISH technique to detect Trisomy 8.
